But, in the GEMINI trials, tolebrutinib failed the primary endpoint of besting Sanofi’s own approved MS drug Aubagio when it came to reducing relapses over up to 36 months. Trying to find the ...
In that trial, the Sanofi drug candidate slowed disability progression when compared with a placebo, an ineffective dummy drug. "Tolebrutinib represents an unprecedented breakthrough as a ...
Some results have been hidden because they may be inaccessible to you